Immune & Wellness Support
A thymus-derived peptide with a substantial international clinical literature in immune regulation.
Pricing reflects the compounded preparation and doctor review. Final therapy and dosing are determined only after your intake is reviewed.
Overview
Thymosin alpha-1 is a 28-amino-acid peptide produced by the thymus gland. It is approved as a medicine in a number of countries for immune indications and has one of the larger evidence bases among peptides in this category.
Subcutaneous injection, commonly two or more times weekly. Your doctor sets the schedule based on your intake.
Your doctor determines the final testing requirements for Thymosin Alpha-1 after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.
How it works
What has been studied
These areas are commonly discussed within wellness-focused protocols. They are educational statements, not medical claims or guarantees of outcome.
Doctor-guided
Your doctor determines the final testing requirements for Thymosin Alpha-1 after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.
Bloodwork status: Recent Labs Recommended
CBC with differential is often repeated at 8 to 12 weeks alongside a review of immune symptom burden.
Your doctor reviews all prescriptions, supplements, and over-the-counter medications during intake before anything is prescribed.
Subcutaneous injection, commonly two or more times weekly. Your doctor sets the schedule based on your intake.
Safety
Regulatory status: Compounded. Evidence level: Moderate. Eligibility, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed doctor after review of your history.
Common questions
Keep exploring
Ready when you are
Fill out a short intake form and our care team will build a plan grounded in your labs — not a guess from a supplement aisle.
